我們已在上線！進一步了解

Organon & Co

OGN

市值 US$36.1億

13.76 USD

0.00

0%

收盤時已更新 10月16日下午4:00 EDT

盤前交易

盤後交易

13.76

0.00

0%

1天

0%

5天

-0.29%

1個月

0.66%

3個月

2%

6個月

47.48%

今年迄今

90.06%

1年

46.7%

5年

-60.46%

10年

-58.62%

關於： Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.

員工： 10,000

醫療保健藥品製造商－一般

新聞

正面

中性

負面

市場情緒 3個月

正面 46.7%

中性 46.7%

負面 6.7%

Organon Announces Positive Interim Phase 3 Study Results for MIUDELLA®, a Hormone-Free, Intrauterine Device (IUD), Through 6 Years of Use to Be Presented at the 2026 Society of Family Planning Annual Meeting

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon reports positive interim Phase 3 results for MIUDELLA®, a hormone-free IUD, through 6 years of use with no new safety signals.

Organon Announces Positive Interim Phase 3 Study Results for MIUDELLA®, a Hormone-Free, Intrauterine Device (IUD), Through 6 Years of Use to Be Presented at the 2026 Society of Family Planning Annual Meeting

Zacks Investment Research

Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know

Recently, Zacks.com users have been paying close attention to Organon (OGN). This makes it worthwhile to examine what the stock has in store.

Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know

Zacks Investment Research

Here is What to Know Beyond Why Organon & Co. (OGN) is a Trending Stock

Organon (OGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Here is What to Know Beyond Why Organon & Co. (OGN) is a Trending Stock

Organon to Present New Real-World Analysis of VTAMA® (tapinarof) Cream, 1%, at the 2026 Fall Clinical Dermatology Conference

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon to unveil first large-scale real-world effectiveness analyses of VTAMA (tapinarof) cream, 1% in patients with eczema at Fall Clinical.

Organon to Present New Real-World Analysis of VTAMA® (tapinarof) Cream, 1%, at the 2026 Fall Clinical Dermatology Conference

Zacks Investment Research

Is Trending Stock Organon & Co. (OGN) a Buy Now?

Organon (OGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Is Trending Stock Organon & Co. (OGN) a Buy Now?

Organon Announces US FDA Has Accepted for Review a Supplemental New Drug Application for MIUDELLA®, a Hormone-Free Intrauterine Device

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon announces FDA accepts MIUDELLA® sNDA for review, seeking to extend approved hormone-free IUD use from 3 to 6 years in the U.S.

Organon Announces US FDA Has Accepted for Review a Supplemental New Drug Application for MIUDELLA®, a Hormone-Free Intrauterine Device

Zacks Investment Research

Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know

Zacks.com users have recently been watching Organon (OGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know

National Can-RISE Study to Help Close Critical Gaps in Menopause Research

TORONTO, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Women's Health Collective Canada (WHCC) and the Partnership for Women's Health Research Canada (PWHR), in partnership with GreenShield and supported by a charitable grant from Organon, have launched the Researching Information, Support, and Equity During the Menopause Transition in Canada (Can-RISE) Study. As the first national investigator-led study focused on Canadian women's experiences of menopause and the menopausal transition, Can-RISE is led by PWHR with funding support from WHCC.

National Can-RISE Study to Help Close Critical Gaps in Menopause Research

Organon Opens REMS Program for MIUDELLA® Ahead of Anticipated Commercial Availability

JERSEY CITY, N.J.--(BUSINESS WIRE)--HCPs, healthcare settings and pharmacies can begin REMS certification for Organon's hormone-free copper IUD, MIUDELLA, ahead of upcoming launch.

Organon Opens REMS Program for MIUDELLA® Ahead of Anticipated Commercial Availability

Zacks Investment Research

Compared to Estimates, Organon (OGN) Q2 Earnings: A Look at Key Metrics

Although the revenue and EPS for Organon (OGN) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Compared to Estimates, Organon (OGN) Q2 Earnings: A Look at Key Metrics

查看新聞排名

價格圖表採用Lightweight Charts™實作